Allergy immunotherapy Market Size

ID: MRFR/HC/0988-CR

200 Pages

Rahul Gotadki

August 2019

Allergy Immunotherapy Market Research Report: Size, Share, Trend Analysis By Types (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies), By Patient Type (Pediatric, Adult, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Allergy immunotherapy Market Infographic

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Allergy Immunotherapy Size

Allergy immunotherapy Market Growth Projections and Opportunities

The Allergy Immunotherapy Market is expected to reach USD 4.9 billion by 2030, at a CAGR of 10.8% during the forecast decade. The market for Allergy Immunotherapy is notably-impacted by an array of market factors which as a whole determine the direction and rate of growth of the market. The most important part of this is the increasing frequency of allergy disorders globally. As of late, more and more people been reported to be suffering from allergies, therefore the market for the allergy therapy treatment became very prominent over the years. Allergy awareness and grasp among healthcare workers and the general public also form the base for increased market growth.

The policy of government and the healthcare system hold the most striking factor in the evolution of the Allergy Immunotherapy sector. A balanced regulatory environment with advantageous reimbursement policies leads to the wider use of allergic immunotherapy treatment that in turn, contributes to the market expansion of these treatments. Aside from that, the development of the market is fostered by the emphasis on preventive healthcare and by other regulatory authorities in promoting more advanced therapies.

Allergy immunotherapy technology is updated with the development of many innovative technologies that affect market dynamics. The constant studies and advancing in science allowing the emergence of new more effective and safe treatments. Therefore, this becomes a circular process that generates the market as the healthcare specialists and patients demand more holistic and secure allergy immunotherapy choices.

Collaborative efforts of the major players, like pharmaceutical companies and research organizations, are an important foundation of the progress in the field of allergy immunotherapy. Through partnerships, mergers, and acquisitions, resources and fortes of enterprises are integrated, accelerating the speed of introduction of innovative products to the market. In line with this, these alliances continue to make the market more competitive and sustainable.

The patients’ preferences and the general condition of personalized medicine are affecting the Allergy Immunotherapy market opportunity. With patients looking for personally targeted treatment which addresses allergic symptoms, the need for more personalized allergy immunotherapy options goes up. This is the reason pharmaceutical companies play around with this approach and they are getting more customized treatment, added diversity in the market.

The economic parameters like the total healthcare spending and the availability level of the disposable income on the other hand are what influence the affordability and the accessibility of allergy immunotherapy. The fact that consumers are ready to buy lasting allergy management products become a rising factor in market growth. Apart from this the stability of economies and the global development of healthcare infrastructure in the emerging markets also results in the growth of the allergy immunotherapy market on a global scale.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the current valuation of the Allergy Immunotherapy Market as of 2024?

The Allergy Immunotherapy Market was valued at 2.83 USD Billion in 2024.

What is the projected market size for the Allergy Immunotherapy Market by 2035?

The market is projected to reach 7.627 USD Billion by 2035.

What is the expected CAGR for the Allergy Immunotherapy Market during the forecast period 2025 - 2035?

The expected CAGR for the market during the forecast period is 9.43%.

Which segment of the Allergy Immunotherapy Market had the highest valuation in 2024?

In 2024, Sublingual Immunotherapy had the highest valuation at 1.2 USD Billion.

What are the projected values for Subcutaneous Immunotherapy by 2035?

Subcutaneous Immunotherapy is projected to reach 2.25 USD Billion by 2035.

Which product category is expected to grow the most in the Allergy Immunotherapy Market?

Conventional Immunotherapy is anticipated to grow significantly, with a projected value of 3.2 USD Billion by 2035.

What is the market valuation for Allergic Rhinitis in 2024?

Allergic Rhinitis was valued at 1.2 USD Billion in 2024.

How does the market for Adult patients compare to Pediatric patients in 2024?

In 2024, the market for Adult patients was valued at 1.5 USD Billion, compared to 0.85 USD Billion for Pediatric patients.

Which key players are leading the Allergy Immunotherapy Market?

Key players include Allergopharma, Anergis, ALK-Abello, and Merck Group, among others.

What is the projected value for Food Allergies in the Allergy Immunotherapy Market by 2035?

The market for Food Allergies is projected to reach 0.53 USD Billion by 2035.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per Market Research Future analysis, the Allergy Immunotherapy Market Size was estimated at 2.83 USD Billion in 2024. The Allergy Immunotherapy industry is projected to grow from 3.097 USD Billion in 2025 to 7.627 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.43% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Allergy Immunotherapy Market is poised for substantial growth driven by technological advancements and increasing awareness.

Technological advancements in treatment are enhancing the efficacy of allergy immunotherapy. North America remains the largest market, while Asia-Pacific is emerging as the fastest-growing region. Subcutaneous immunotherapy continues to dominate the market, whereas sublingual immunotherapy is witnessing rapid growth. Rising allergy prevalence and increased investment in allergy research are key drivers propelling market expansion.

Allergy immunotherapy Market

CAGR

9.43%

Market Size & Forecast

2024 Market Size	2.83 (USD Billion)
2035 Market Size	7.627 (USD Billion)
CAGR (2025 - 2035)	9.43%
Largest Regional Market Share in 2024	North America

Major Players

<a href="https://allergopharma.dermapharm.com/en-en/products/allergen-immunotherapy-ait/">Allergopharma </a>(DE), Anergis (CH), ALK-Abello (DK), Merck Group (DE), Stallergenes Greer (GB), HollisterStier Allergy (US), Circassia Pharmaceuticals (GB), DBV Technologies (FR), Rho (US)

Market Trends

The Allergy Immunotherapy Market is currently experiencing a notable transformation, driven by an increasing prevalence of allergic conditions worldwide which is also contributing to the expansion of the broader allergy treatment market. This rise in allergies has prompted a growing demand for effective treatment options, leading to heightened interest in immunotherapy as a viable solution. The market appears to be evolving with advancements in technology and research, which may enhance the efficacy and safety of immunotherapy treatments. Furthermore, the integration of personalized medicine into allergy management is likely to play a crucial role in shaping future therapeutic approaches. As healthcare providers and patients alike seek more tailored solutions, the Allergy Immunotherapy Market is poised for significant growth. In addition to technological advancements, regulatory support is becoming increasingly evident, as governments and health organizations recognize the importance of addressing allergy-related health issues. This support may facilitate the development and approval of new immunotherapy products, thereby expanding treatment options for patients. Moreover, the rising awareness of allergies and their impact on quality of life is likely to drive patient engagement and adherence to treatment protocols. Overall, the Allergy Immunotherapy Market seems to be on a promising trajectory, with various factors converging to create a dynamic and responsive landscape for allergy management.

Technological Advancements in Treatment

The Allergy Immunotherapy Market is witnessing a surge in innovative treatment modalities, including sublingual and injectable immunotherapies. These advancements may enhance patient compliance and improve therapeutic outcomes, as they offer more convenient administration routes and potentially fewer side effects.

Personalized Medicine Integration

There is a growing trend towards personalized medicine within the Allergy Immunotherapy Market reflecting broader developments in the allergy care market. Tailoring treatments to individual patient profiles could lead to more effective management of allergic conditions, as healthcare providers increasingly focus on genetic and environmental factors influencing patient responses.

Regulatory Support and Development

Regulatory bodies are increasingly recognizing the significance of allergy management, leading to enhanced support for the Allergy Immunotherapy Market. This trend may result in expedited approval processes for new therapies, thereby broadening the range of available treatment options for patients.

Allergy immunotherapy Market Market Drivers

Rising Allergy Prevalence

The Allergy Immunotherapy Market is experiencing growth due to the increasing prevalence of allergic conditions worldwide. Allergies, including allergic rhinitis and asthma, affect millions of individuals, leading to a heightened demand for effective treatment options. Recent estimates suggest that approximately 30% of the global population suffers from some form of allergy, which underscores the urgent need for innovative therapies. This rising incidence is prompting healthcare providers to seek advanced immunotherapy solutions, thereby driving market expansion. Furthermore, the growing awareness of the long-term benefits of immunotherapy over traditional symptomatic treatments is likely to enhance patient adoption rates. As more individuals seek relief from allergy symptoms, the Allergy Immunotherapy Market is poised for significant growth in the coming years.

Growing Awareness and Education

The Allergy Immunotherapy Market is experiencing growth driven by increased awareness and education regarding allergic conditions and their treatments. Public health campaigns and educational initiatives are informing patients about the benefits of immunotherapy, which is often underutilized. As more individuals become aware of the long-term advantages of allergy immunotherapy, such as reduced reliance on medications and improved quality of life, the demand for these treatments is expected to rise. Furthermore, healthcare professionals are increasingly advocating for immunotherapy as a viable treatment option, contributing to a shift in patient perceptions. This growing awareness is likely to play a crucial role in expanding the Allergy Immunotherapy Market as more patients seek effective solutions for their allergies.

Advancements in Immunotherapy Techniques

Technological innovations are playing a pivotal role in shaping the Allergy Immunotherapy Market. Recent advancements in treatment methodologies, such as sublingual immunotherapy and monoclonal antibodies, are enhancing the efficacy and safety profiles of allergy treatments. These innovations are not only improving patient outcomes but also expanding the range of allergens that can be effectively treated. For instance, the introduction of personalized immunotherapy approaches, which tailor treatment based on individual patient profiles, is gaining traction. This shift towards more targeted therapies is expected to attract a broader patient base, thereby propelling market growth. As these advancements continue to evolve, the Allergy Immunotherapy Market is likely to witness a surge in demand for novel treatment options.

Increased Investment in Allergy Research

The Allergy Immunotherapy Market is benefiting from increased investment in allergy research and development. Governments and private entities are recognizing the economic burden associated with allergic diseases, which has led to enhanced funding for innovative treatment solutions. In recent years, research funding has seen a notable uptick, with millions allocated to studies focused on immunotherapy. This financial support is fostering the development of new therapies and improving existing ones, thereby expanding the market landscape. Additionally, collaborations between academic institutions and pharmaceutical companies are becoming more prevalent, further driving innovation in the Allergy Immunotherapy Market. As research continues to advance, the potential for breakthrough therapies is likely to increase, attracting further investment.

Regulatory Support for Innovative Therapies

The Allergy Immunotherapy Market is being positively influenced by regulatory support for innovative therapies. Regulatory agencies are increasingly recognizing the importance of immunotherapy in managing allergic conditions and are streamlining the approval processes for new treatments. This supportive regulatory environment is encouraging pharmaceutical companies to invest in the development of novel immunotherapy products. Recent initiatives aimed at expediting the review of allergy treatments are likely to enhance the availability of new therapies in the market. As regulatory frameworks continue to evolve, the Allergy Immunotherapy Market is expected to benefit from a more favorable landscape for innovation and product launches.

Market Segment Insights

By Type: Subcutaneous Immunotherapy (Largest) vs. Sublingual Immunotherapy (Fastest-Growing)

The Allergy Immunotherapy Market exhibits a diverse landscape with several types of therapies vying for dominance. Among them, Subcutaneous Immunotherapy stands out as the largest segment, capturing the majority of the market share due to its longstanding acceptance and established efficacy. On the other hand, Sublingual Immunotherapy has emerged as a significant competitor, particularly favored by patients for its ease of administration. At the same time, Oral Immunotherapy is gradually gaining traction, though it currently holds a smaller share compared to the more traditional therapies. Growth trends within the Allergy Immunotherapy Market are influenced by several factors, such as rising allergy prevalence and advancing research. The convenience of Sublingual and Oral Immunotherapy is making them increasingly popular, particularly among patients seeking alternatives to traditional methods. Furthermore, regulatory approvals and a growing body of clinical evidence supporting these therapies continue to push their adoption rates, indicating a promising trajectory for the future of the Immunotherapy Market.

Subcutaneous Immunotherapy (Dominant) vs. Sublingual Immunotherapy (Emerging)

Subcutaneous Immunotherapy is considered the dominant player in the Allergy Immunotherapy Market, well-established with numerous clinical trial backing its effectiveness for various allergic conditions. This segment provides comprehensive treatment options, often involving multiple injections over a specified period to achieve desensitization. In contrast, Sublingual Immunotherapy represents the emerging trend, appealing especially to patients who prefer a more convenient, less invasive treatment. Its administration as drops or tablets allows for easier compliance, fostering a growing acceptance among healthcare providers and patients alike. Both segments showcase distinct characteristics catering to diverse patient preferences, making the competition in the market increasingly dynamic.

By Product: Allergen Extracts (Largest) vs. Biologics (Fastest-Growing)

The Allergy Immunotherapy Market is experiencing significant segmentation, with allergen extracts holding the largest market share. This segment has been well-established due to its traditional use in treating various allergies, leading to its dominance in the market. In contrast, biologics, which utilize the body’s immune system to combat allergens, are rapidly emerging as a compelling alternative due to increasing awareness and advancements in technology. Their share is steadily rising as they provide targeted therapies with potentially fewer side effects, appealing to both healthcare providers and patients alike.

Allergen Extracts (Dominant) vs. Biologics (Emerging)

Allergen extracts represent the dominant force within the Allergy Immunotherapy Market. These extracts, derived from a variety of allergens such as pollen, dust mites, and mold, have a long-standing history of efficacy in alleviating allergic reactions. Their proven track record and established use in conventional immunotherapy have solidified their market position. On the other hand, <a href="https://www.marketresearchfuture.com/reports/biologics-market-1339">biologics </a>are an emerging segment characterized by innovative therapies that harness biological processes. With their potential to offer personalized treatment options, biologics are experiencing rapid growth, driven by increasing demand for targeted therapies and advancements in biotechnology. This growth highlights the evolving landscape of allergy treatment, pushing both segments into a competitive but complementary existence.

By Indication: Allergic Rhinitis (Largest) vs. Food Allergies (Fastest-Growing)

In the Allergy Immunotherapy Market, the indications of <a href="https://www.marketresearchfuture.com/reports/allergic-rhinitis-market-1547">Allergic Rhinitis</a>, Allergic Asthma, Atopic Dermatitis, and Food Allergies together constitute a significant part of the overall market landscape. Among these, Allergic Rhinitis holds the largest share, attributed to its prevalence and heightened awareness of treatment options. Following this, Allergic Asthma and Atopic Dermatitis also contribute notably, while Food Allergies represent a growing concern that is increasingly gaining traction within the market.

Allergic Rhinitis (Dominant) vs. Food Allergies (Emerging)

Allergic Rhinitis has emerged as the dominant indication in the Allergy Immunotherapy Market, primarily due to its widespread incidence and the availability of effective treatment options. Patients suffering from Allergic Rhinitis are typically seeking relief from the symptoms associated with seasonal and perennial allergies, driving demand for immunotherapy solutions. In contrast, Food Allergies are considered an emerging segment, reflecting increasing incidences and a rising awareness of dietary-related allergies. The rapid growth in this area can be attributed to factors such as the evolving understanding of food allergens, innovative therapeutic developments, and a growing focus on preventive measures in pediatric populations. Together, these segments illustrate a dynamic landscape within the Allergy Immunotherapy Market.

By Patient Type: Adult (Largest) vs. Pediatric (Fastest-Growing)

In the Allergy Immunotherapy Market, the distribution of patient types reveals that adults represent the largest segment due to their higher susceptibility to allergic reactions and the ongoing prevalence of allergy-related illnesses. This demographic is increasingly seeking effective long-term treatment options, resulting in a significant portion of the market share allocated to adult patients. Conversely, the pediatric segment, though smaller in current market share, is witnessing rapid growth. This increase is mainly attributed to the rising awareness among parents regarding childhood allergies and the importance of early intervention in prevention and treatment. Growth trends indicate a surge in the demand for effective allergy treatments tailored to different age groups. Pediatric patients are emerging as a critical focus area, driven by advancements in formulation and treatment protocols specifically designed for younger populations. The growing prevalence of allergies in children and increased healthcare access are boosting the pediatric immunotherapy segment's expansion, while adult treatments continue to dominate due to established practices and ongoing research to enhance efficacy and safety in this age group.

Adult (Dominant) vs. Pediatric (Emerging)

The Adult segment in the Allergy Immunotherapy Market holds a dominant position, characterized by a well-established understanding of adult allergies and a wide array of treatment options. This segment benefits from extensive clinical research and a variety of immunotherapeutic formulations that target common allergens such as pollen, dust mites, and pet dander. Adults are more likely to recognize and seek treatment for their allergies, leading to a sustained demand for immunotherapy solutions. In contrast, the Pediatric segment is emerging rapidly due to a focus on developing specialized treatments that are safe and effective for younger patients. This segment not only addresses allergy treatment but also emphasizes preventive care, engaging parents in the educational aspect of managing childhood allergies. As a result, this dual approach to treatment gives both segments unique but complementary market positions.

Get more detailed insights about Allergy Immunotherapy Market Research Report - Global Forecast till 2035

Regional Insights

The Allergy Immunotherapy Market is witnessing significant growth across its regional segmentation. In 2024, North America leads the market with a valuation of 2.35 USD Billion, driven by high prevalence rates of allergies and advanced healthcare infrastructure. Europe follows with a substantial valuation of 1.7 USD Billion, fueled by an increasing awareness of allergic conditions and improved diagnostic techniques.

South America, with a market value of 0.4 USD Billion, holds potential due to rising healthcare access in developing countries, while Asia Pacific is valued at 0.9 USD Billion, highlighting the growing demand for allergen-specific treatments in densely populated regions.The Middle East and Africa represent a smaller segment valued at 0.36 USD Billion, yet are emerging markets with increasing focus on allergy treatments. Each region significantly contributes to the Allergy Immunotherapy Market revenue, with North America and Europe dominating due to a combination of high healthcare expenditures and robust Research and Development initiatives.

The overall market growth is influenced by rising allergy incidences and an emphasis on personalized medicine, highlighting opportunities across all regions for future advancements in allergic disease management.

Key Players and Competitive Insights

The Allergy Immunotherapy Market is characterized by growing competition as significant developments in the field of immunotherapy, biotechnology, and pharmaceuticals continue to shape the landscape. Several key players have emerged, driving innovation and expanding their product offerings to cater to a rising number of allergy sufferers worldwide. The market is witnessing an increase in strategic collaborations, partnerships, and mergers as companies seek to enhance their portfolio, broaden their geographic reach, and leverage the expertise of others within the industry. The competitive dynamics are further influenced by the growing awareness of allergy and immunotherapy treatments, leading to the introduction of advanced therapy options that improve patient outcomes and provide therapists with more effective solutions.Novartis has established a prominent position within the Allergy Immunotherapy Market by leveraging its comprehensive portfolio of innovative therapies and a strong global footprint. The company's commitment to research and development has resulted in the introduction of advanced allergy immunotherapy products that address various forms of allergic reactions. A notable strength of Novartis lies in its ability to effectively navigate regulatory landscapes, enabling timely product approvals and market entry in diverse regions. This, combined with robust distribution channels and strategic collaborations, has allowed Novartis to solidify its presence in the allergy immunotherapy space. Their ongoing investment in research and patient engagement initiatives further enhances their standing as a key player in providing meaningful solutions for allergy sufferers worldwide.Hal Allergie is actively involved in the Allergy Immunotherapy Market, offering a range of immunotherapy solutions designed to address different allergic conditions. Their key products include various allergy vaccines and diagnostic tools that cater to specific allergens, enhancing their market presence. Hal Allergie has built a reputation for delivering high-quality allergen immunotherapy treatments, aided by their commitment to innovation and stringent production standards. Their strength in the market is underscored by a solid distribution network and strategic collaborations that facilitate their growth in global regions. The company has also pursued mergers and acquisitions to expand its product portfolio and capabilities, further positioning itself as a reliable provider in the allergy immunotherapy segment. Through these efforts, Hal Allergie aims to maintain its competitive edge and continue contributing to advancements in allergy treatment globally.

Key Companies in the Allergy immunotherapy Market include

Industry Developments

Recent developments in the Allergy Immunotherapy Market have been significant, particularly with advancements in treatment options and company positioning. In October 2023, Aimmune Therapeutics announced promising results from its clinical trials on peanut allergy treatments, further validating the efficacy of immunotherapy. Meanwhile, Novartis has focused on expanding its portfolio in allergy treatments, partnering with several biotech firms to enhance its Research and Development pipeline.

Current affairs also reveal that Merck Group has launched new combination therapies that aim to improve patient outcomes in allergy management. Over the last two years, market valuation has seen a steady increase, attributed to rising allergy prevalence and innovative treatments like sublingual immunotherapy gaining acceptance. The market growth is further fueled by ongoing regulatory support for allergy treatment innovations, indicating a robust future for the Allergy Immunotherapy Market.

Future Outlook

Allergy immunotherapy Market Future Outlook

The Allergy Immunotherapy Market is projected to grow at a 9.43% CAGR from 2025 to 2035, driven by increasing allergy prevalence, technological advancements, and rising consumer awareness.

New opportunities lie in:

Development of personalized immunotherapy solutions for specific allergens. Expansion of telehealth platforms for remote allergy consultations. Investment in AI-driven diagnostics for enhanced patient targeting.

By 2035, the market is expected to achieve substantial growth, driven by innovation and increased accessibility.

Market Segmentation

Allergy immunotherapy Market Type Outlook

Subcutaneous Immunotherapy
Sublingual Immunotherapy
Oral Immunotherapy

Allergy immunotherapy Market Product Outlook

Allergen Extracts
Conventional Immunotherapy
Biologics

Allergy immunotherapy Market Indication Outlook

Allergic Rhinitis
Allergic Asthma
Atopic Dermatitis
Food Allergies

Allergy immunotherapy Market Patient Type Outlook

Pediatric
Adult
Geriatric

Report Scope

MARKET SIZE 2024	2.83(USD Billion)
MARKET SIZE 2025	3.097(USD Billion)
MARKET SIZE 2035	7.627(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	9.43% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Allergopharma (DE), Anergis (CH), ALK-Abello (DK), Merck Group (DE), Stallergenes Greer (GB), HollisterStier Allergy (US), Circassia Pharmaceuticals (GB), DBV Technologies (FR), Rho (US)
Segments Covered	Types, Product, Indication, Patient Type, Regional
Key Market Opportunities	Integration of digital health technologies enhances patient engagement in the Allergy Immunotherapy Market.
Key Market Dynamics	Rising consumer awareness and regulatory support drive growth in the Allergy Immunotherapy Market, enhancing treatment accessibility.
Countries Covered	North America, Europe, APAC, South America, MEA